1
TITLE: KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer
AUTHORS: Rugo, Hope S.; Sohn, Joohyuk; Jerez Gilarranz, Yolanda; Gonzalez Cortijo, Lucia; Sonnenblick, Amir; Sabanathan, Dhanusha; Pablo Korbenfeld, Ernesto; Egle, Daniel; Poirier, Brigitte; Zagouri, Flora; Matikas, Alexios; Aksoy, Sercan; Demirci, Umut; Ramos Elias, Pier; Im, Seock Ah; Cardoso, Fatima; Jia, Liyi; Baccan, Carlos; Tryfonidis, Konstantinos; Schmid, Peter;
PUBLISHED: 2022, SOURCE: JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 40, ISSUE: 16
INDEXED IN: WOS
2
TITLE: Phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer (mBC): KEYNOTE-B49  Full Text
AUTHORS: Schmid, Peter; Sohn, Joo Hyuk; Jerez Gilarranz, Yolanda; Gonzalez Cortijo, Lucia; Sonnenblick, Amir; Sabanathan, Dhanusha; Korbenfeld, Ernesto; Egle, Daniel; Poirier, Brigitte; Zagouri, Flora; Matikas, Alexios; Aksoy, Sercan; Demirci, Umut; Ramos Elias, Pier; Im, Seock Ah; Cardoso, Fatima; Jia, Liyi; Hirshfield, Kim; Tryfonidis, Konstantinos; Rugo, Hope S.;
PUBLISHED: 2022, SOURCE: ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 18
INDEXED IN: WOS